Dr Reddy’s Laboratories ( ($RDY) ) has shared an update. On February 4, 2025, Dr. Reddy’s Laboratories announced its participation in an investor ...

An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. On February 4, 2025, Dr. Reddy’s Laboratories announced its ...

Dr. Reddy's Laboratories Ltd. closed 14.12% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Laboratories Ltd. closed 14.27% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Crossmark Global Holdings Inc. grew its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 328.3% in the fourth quarter, Holdings Channel reports. The firm owned 12,760 ...

Barclays analyst Balaji Prasad maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report) today and set a price target of ...

Indian shares inched higher on Friday, tracking Asian peers after U.S. President Donald Trump said he would push for lower interest rates, while worries over moderation in domestic earnings capped ...

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide.

Ladies and gentlemen, good day and welcome to the Quarter Three FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participant lines will be in the listen-only ...

FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion.

HYDERABAD, India (AP) — HYDERABAD, India (AP) — Dr. Reddy's Laboratories Ltd. (RDY) on Thursday reported profit of $167.3 million in its fiscal third quarter. The Hyderabad, India-based company said ...